Attributes | Values |
---|
rdf:type
| |
Description
| - Léčba chronické myeloidní leukémie (CML) rezistentní na imatinib (IM) je obohacena o druhou generaci tyrozinkinázových inhibitorů (TKI), o dasatinib (DAS) a nilotinib. Rozhodnutí o změně terapie lze podpořit testem citlivosti leukemických buněk na jednotlivé TKI in vitro, který umožňuje sledovat míru účinnosti TKI na základě detekce inhibice fosforylace signálních molekul, které jsou substrátem Bcr-Abl tyrozinkinázy. (cs)
- Background. Second generation Abl tyrosine kinase inhibitors (TKIs), such as dasatinib (DAS) or nilotinib, are currently available for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib (IM) therapy. The efficacy of TKIs can be evaluated in vitro by degree of inhibition of phosphorylation of selected signaling molecules downstream Bcr-Abl after incubation of leukocytes with the drug. Aim. To evaluate functional assay that enables the clinicians to predict therapy responses and the degree of resistance/sensitivity of Bcr-Abl-positive leukemia patients to TKIs. Methods. Quantitative real time RT-PCR (Q-RT-PCR) was performed to monitor the level of BCR-ABL transcripts. BCR-ABL mutational status was assessed using sequencing of the RT-PCR products. The in vitro test of sensitivity to TKIs was based on detection of inhibition of phosphorylation of Crkl and Phospho-Src Family kinases (SFK, Tyr416). The pellet of leukocytes was washed with Optimem I (Gibco) a
- Background. Second generation Abl tyrosine kinase inhibitors (TKIs), such as dasatinib (DAS) or nilotinib, are currently available for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib (IM) therapy. The efficacy of TKIs can be evaluated in vitro by degree of inhibition of phosphorylation of selected signaling molecules downstream Bcr-Abl after incubation of leukocytes with the drug. Aim. To evaluate functional assay that enables the clinicians to predict therapy responses and the degree of resistance/sensitivity of Bcr-Abl-positive leukemia patients to TKIs. Methods. Quantitative real time RT-PCR (Q-RT-PCR) was performed to monitor the level of BCR-ABL transcripts. BCR-ABL mutational status was assessed using sequencing of the RT-PCR products. The in vitro test of sensitivity to TKIs was based on detection of inhibition of phosphorylation of Crkl and Phospho-Src Family kinases (SFK, Tyr416). The pellet of leukocytes was washed with Optimem I (Gibco) a (en)
|
Title
| - Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients
- Význam testu sensitivity leukemický buněk na inhibitory kináz in vitro při rozhodování o léčbě imatinibem a dasatinibem u nemocných s CML (cs)
- Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients (en)
|
skos:prefLabel
| - Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients
- Význam testu sensitivity leukemický buněk na inhibitory kináz in vitro při rozhodování o léčbě imatinibem a dasatinibem u nemocných s CML (cs)
- Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients (en)
|
skos:notation
| - RIV/61989592:15110/08:00007429!RIV09-MSM-15110___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/08:00007429
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - chronic myeloid leukemia; tyrosine kinase inhibitor; imatinib resistance; src kinase (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Haematologica: the hematology journal
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Faber, Edgar
- Indrák, Karel
- Jarošová, Marie
- Rožmanová, Šárka
- Holzerová, Milena
- Divoký, Vladimír
- Mojzíková, Renáta
- Veselovská, Jitka
|
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |